🔎 Trials Near Me

Início › Leucemia Mieloide Aguda › Carolina do Norte › Durham

Ensaios clínicos de Leucemia Mieloide Aguda em Durham, NC

33 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Durham e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.

Texto oficial do estudo (Inglês)

Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RecrutandoFase 2
  • Duke University Medical Center, Durham
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT05564390

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
  • Durham VA Medical Center, Durham
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • Duke University Medical Center, Durham
Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • Duke University Medical Center, Durham
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • Duke University Medical Center, Durham
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • Duke University Medical Center, Durham
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RecrutandoFase 3
  • Duke University Medical Center, Durham
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

RecrutandoFase 1/2
  • Duke University Medical Center, Durham
30 Days · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04065399

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

RecrutandoFase 1
  • University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06846606

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

RecrutandoFase 1/2
  • UNC School of Medicine, Division of Hematology, Chapel Hill · a 10 mi de distância
Idades 12 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

RecrutandoFase 3
  • US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · a 10 mi de distância
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

RecrutandoFase 1/2
  • Duke University Medical Center, Durham
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

RecrutandoFase 1
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Idades de 18 a 75 · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT05886049

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RecrutandoFase 3
  • Duke University Medical Center, Durham
  • University of North Carolina, Chapel Hill, Chapel Hill · a 10 mi de distância
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07007312

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

RecrutandoFase 1
  • University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT06656494

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

RecrutandoFase 1/2
  • Research Site, Durham
  • Research Site, Chapel Hill · a 10 mi de distância
Idades 16 e acima · Todos os sexos · Atualizado em 20 de jul. de 2026 · NCT07155226

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

RecrutandoFase 2
  • University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
Idades 18 e acima · Todos os sexos · Atualizado em 10 de jul. de 2026 · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RecrutandoEstudo observacional
  • Duke University Medical Center, Durham
  • University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Recrutando
  • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Idades 60 e acima · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT06697600

Registry of Older Patients With Cancer

RecrutandoEstudo observacional
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · a 10 mi de distância
Idades 65 e acima · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT01137825

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

RecrutandoFase 2
  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
Idades 18 e acima · Todos os sexos · Atualizado em 23 de jun. de 2026 · NCT05401097

A Study of Revumenib and Mezigdomide in People With Leukemia

RecrutandoFase 1/2
  • University of North Carolina (Data Collection Only), Chapel Hill · a 10 mi de distância
Idades 12 e acima · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT07356154

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

RecrutandoFase 1
  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
Idades 18 e acima · Todos os sexos · Atualizado em 14 de mai. de 2026 · NCT06222580

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

RecrutandoFase 1
  • University of North Carolina, Chapel Hill · a 10 mi de distância
Idades 13 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

RecrutandoFase 2/3
  • Duke University, Durham
Idades 18 e acima · Todos os sexos · Atualizado em 30 de abr. de 2026 · NCT04256317

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

RecrutandoFase 1/2
  • Duke University, Durham
  • UNC Hospital, Chapel Hill · a 10 mi de distância
Idades 12 e acima · Todos os sexos · Atualizado em 24 de mar. de 2026 · NCT04988555

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

RecrutandoFase 2
  • University of North Carolina, Chapel Hill · a 10 mi de distância
Idades de 18 a 66 · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06859424

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RecrutandoFase 1
  • Duke Blood Cancer Center, Durham
Idades 18 e acima · Todos os sexos · Atualizado em 13 de mar. de 2026 · NCT05735184

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

RecrutandoFase 1
  • Duke Cancer Center, Durham
Idades 18 e acima · Todos os sexos · Atualizado em 16 de jan. de 2026 · NCT05143996

Novel Digital Application for Patients With Acute Leukemia

Recrutando
  • Duke University, Durham
Idades de 18 a 120 · Todos os sexos · Atualizado em 10 de nov. de 2025 · NCT06472128

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

RecrutandoEstudo observacional
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · a 10 mi de distância
Idades de 18 a 120 · Todos os sexos · Atualizado em 27 de out. de 2025 · NCT01137643

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

RecrutandoFase 1/2
  • Duke University Medical Center, Durham
Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

RecrutandoVoluntários saudáveis bem-vindos
  • Duke University, Durham
  • University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
Idades de 18 a 120 · Todos os sexos · Atualizado em 25 de jul. de 2025 · NCT05237258

Ensaios de Leucemia Mieloide Aguda em outras cidades

Outros estudos em Durham

Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.